232 related articles for article (PubMed ID: 33927413)
1. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.
Berry-Kravis EM; Harnett MD; Reines SA; Reese MA; Ethridge LE; Outterson AH; Michalak C; Furman J; Gurney ME
Nat Med; 2021 May; 27(5):862-870. PubMed ID: 33927413
[TBL] [Abstract][Full Text] [Related]
2. Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).
Gurney ME; Cogram P; Deacon RM; Rex C; Tranfaglia M
Sci Rep; 2017 Nov; 7(1):14653. PubMed ID: 29116166
[TBL] [Abstract][Full Text] [Related]
3. Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome.
Rosenheck M; Sheeler C; Saré RM; Gurney ME; Smith CB
Neurobiol Dis; 2021 Nov; 159():105485. PubMed ID: 34411704
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders.
Gurney ME; Nugent RA; Mo X; Sindac JA; Hagen TJ; Fox D; O'Donnell JM; Zhang C; Xu Y; Zhang HT; Groppi VE; Bailie M; White RE; Romero DL; Vellekoop AS; Walker JR; Surman MD; Zhu L; Campbell RF
J Med Chem; 2019 May; 62(10):4884-4901. PubMed ID: 31013090
[TBL] [Abstract][Full Text] [Related]
5. Effect of lovastatin on behavior in children and adults with fragile X syndrome: an open-label study.
Çaku A; Pellerin D; Bouvier P; Riou E; Corbin F
Am J Med Genet A; 2014 Nov; 164A(11):2834-42. PubMed ID: 25258112
[TBL] [Abstract][Full Text] [Related]
6. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
[TBL] [Abstract][Full Text] [Related]
7. Vocabulary comprehension in adults with fragile X syndrome (FXS).
Hoffmann A; Krause SE; Wuu J; Leurgans S; Guter SJ; Block SS; Salt J; Cook E; Maino DM; Berry-Kravis E
J Neurodev Disord; 2019 Oct; 11(1):25. PubMed ID: 31619160
[TBL] [Abstract][Full Text] [Related]
8. Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.
Youssef EA; Berry-Kravis E; Czech C; Hagerman RJ; Hessl D; Wong CY; Rabbia M; Deptula D; John A; Kinch R; Drewitt P; Lindemann L; Marcinowski M; Langland R; Horn C; Fontoura P; Santarelli L; Quiroz JA;
Neuropsychopharmacology; 2018 Feb; 43(3):503-512. PubMed ID: 28816242
[TBL] [Abstract][Full Text] [Related]
9. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome.
Berry-Kravis E; Sumis A; Hervey C; Nelson M; Porges SW; Weng N; Weiler IJ; Greenough WT
J Dev Behav Pediatr; 2008 Aug; 29(4):293-302. PubMed ID: 18698192
[TBL] [Abstract][Full Text] [Related]
10. PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome.
Choi CH; Schoenfeld BP; Weisz ED; Bell AJ; Chambers DB; Hinchey J; Choi RJ; Hinchey P; Kollaros M; Gertner MJ; Ferrick NJ; Terlizzi AM; Yohn N; Koenigsberg E; Liebelt DA; Zukin RS; Woo NH; Tranfaglia MR; Louneva N; Arnold SE; Siegel SJ; Bolduc FV; McDonald TV; Jongens TA; McBride SM
J Neurosci; 2015 Jan; 35(1):396-408. PubMed ID: 25568131
[TBL] [Abstract][Full Text] [Related]
11. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome.
Berry-Kravis E; Horrigan JP; Tartaglia N; Hagerman R; Kolevzon A; Erickson CA; Hatti S; Snape M; Yaroshinsky A; Stoms G; ; Glass L; Jones NE
Pediatr Neurol; 2020 Sep; 110():30-41. PubMed ID: 32660869
[TBL] [Abstract][Full Text] [Related]
12. A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial.
de Diego-Otero Y; Calvo-Medina R; Quintero-Navarro C; Sánchez-Salido L; García-Guirado F; del Arco-Herrera I; Fernández-Carvajal I; Ferrando-Lucas T; Caballero-Andaluz R; Pérez-Costillas L
Trials; 2014 Sep; 15():345. PubMed ID: 25187257
[TBL] [Abstract][Full Text] [Related]
13. Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile x syndrome.
Norris JE; Berry-Kravis EM; Harnett MD; Reines SA; Reese MA; Outterson AH; Michalak C; Furman J; Gurney ME; Ethridge LE
Res Sq; 2024 Jun; ():. PubMed ID: 38946987
[TBL] [Abstract][Full Text] [Related]
14. Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.
Seritan AL; Nguyen DV; Mu Y; Tassone F; Bourgeois JA; Schneider A; Cogswell JB; Cook KR; Leehey MA; Grigsby J; Olichney JM; Adams PE; Legg W; Zhang L; Hagerman PJ; Hagerman RJ
J Clin Psychiatry; 2014 Mar; 75(3):264-71. PubMed ID: 24345444
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
[TBL] [Abstract][Full Text] [Related]
16. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K; Ranasinghe KG; Beagle AJ; La A; Ah Pook K; Castro M; Mizuiri D; Honma SM; Venkateswaran N; Koestler M; Zhang W; Mucke L; Howell MJ; Possin KL; Kramer JH; Boxer AL; Miller BL; Nagarajan SS; Kirsch HE
JAMA Neurol; 2021 Nov; 78(11):1345-1354. PubMed ID: 34570177
[TBL] [Abstract][Full Text] [Related]
17. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
Berry-Kravis E; Krause SE; Block SS; Guter S; Wuu J; Leurgans S; Decle P; Potanos K; Cook E; Salt J; Maino D; Weinberg D; Lara R; Jardini T; Cogswell J; Johnson SA; Hagerman R
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):525-40. PubMed ID: 17069542
[TBL] [Abstract][Full Text] [Related]
18. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.
Leigh MJ; Nguyen DV; Mu Y; Winarni TI; Schneider A; Chechi T; Polussa J; Doucet P; Tassone F; Rivera SM; Hessl D; Hagerman RJ
J Dev Behav Pediatr; 2013 Apr; 34(3):147-55. PubMed ID: 23572165
[TBL] [Abstract][Full Text] [Related]
19. Brain circuitry, behavior, and cognition: A randomized placebo-controlled trial of donepezil in fragile X syndrome.
Bruno JL; Hosseini SH; Lightbody AA; Manchanda MK; Reiss AL
J Psychopharmacol; 2019 Aug; 33(8):975-985. PubMed ID: 31264943
[TBL] [Abstract][Full Text] [Related]
20. Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello C; Tao L; Folino A; Berry-Kravis E; Tranfaglia M; Ethell IM; Ethell DW
BMC Neurol; 2010 Oct; 10():91. PubMed ID: 20937127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
